10x Genomics (Nasdaq: TXG) officially unveiled its latest spatial biology innovation, the Atera platform, during a global launch event on April 20, 2026. Designed to address the growing demand for high-throughput, whole-transcriptome mapping, Atera represents a significant expansion of the company’s spatial portfolio, which already includes the Visium and Xenium product lines. The new platform is engineered to provide researchers with the ability to analyze tens of thousands of genes simultaneously across large tissue sections with subcellular resolution.
The Atera system introduces several technical advancements intended to streamline the transition from discovery-based research to large-scale clinical studies. According to technical specifications released by the company, Atera utilizes a proprietary Spatial-Link chemistry that allows for the detection of over 20,000 gene targets per sample. The platform features an automated workflow capable of processing up to 32 slides per run, a fourfold increase in throughput compared to previous-generation spatial instruments. This capacity is specifically aimed at pharmaceutical companies and large academic core facilities requiring high-volume data generation for drug target identification and biomarker validation.
Serge Saxonov, Co-founder and CEO of 10x Genomics, stated that Atera was developed to remove the trade-offs between resolution and scale that have historically limited spatial transcriptomics. Saxonov noted that the platform integrates directly with the company’s existing software ecosystem, including the 10x Cloud and the Xenium Explorer visualization suite. This integration allows for the cross-referencing of high-plex protein data with whole-transcriptome maps, providing a multi-omic view of the tissue microenvironment. The company confirmed that Atera is compatible with both fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tissue types, which are standard in clinical pathology.
The launch of Atera comes at a time when 10x Genomics is intensifying its focus on the translational research market. The company announced that early access programs for Atera will begin in the third quarter of 2026, with full commercial shipping expected to commence by the end of the year. While specific unit pricing was not disclosed, the company indicated that the platform’s cost-per-sample has been optimized for large-scale studies, potentially reducing the financial barrier for whole-transcriptome spatial projects. Chief Technology Officer Ben Hindson highlighted that the platform’s hardware includes a new high-speed imaging module and advanced fluidics designed to minimize reagent consumption while maintaining data sensitivity.
In addition to the hardware, 10x Genomics introduced a new suite of Atera-specific consumables, including high-density sensor chips and optimized library preparation kits. These components are designed to work in tandem with the Atera instrument to ensure reproducible results across different laboratory environments. The company also detailed a partnership with several leading oncology centers to utilize Atera for the mapping of tumor heterogeneity in large patient cohorts. These collaborations are expected to generate foundational datasets that will be made available to the broader scientific community through the 10x Genomics Data Portal.